Sensex heatmap at close: Yes Bank tops with 8.4% gain, RIL up 1.6%, Tata Motors slips 3%##Sensex heatmap at close: Yes Bank tops with 8.4% gain, RIL up 1.6%, Tata Motors slips 3%

Jan 24, 2019 4:04 PM

Closing Bell: Sensex, Nifty settle with mild gains led by Reliance Industries, Yes Bank##Closing Bell: Sensex, Nifty settle with mild gains led by Reliance Industries, Yes Bank

The Sensex settled almost 87 points high, or 0.24 percent, at 36,195 at close. The Nifty ended at 10,850, up by just 18 points, or 0.17 percent. The Nifty MidCap underperformed, down by 0.34 percent.The BSE MidCap slipped 0.15 percent. Yes Bank shares jumped 15%, eventually settling over 9% up after Ravneet Gill was announced as the private lender's new CEO and MD. Reliance, TCS, JSW Steel, Tech Mahindra were other major gainers rising between 1 and 2 percent. Bharti Infratel, Tata Motors, UPL, Sun Pharma and Cipla shares dipped between 1.7 percent and 5 percent.

Jan 24, 2019 3:56 PM

Yes Bank sees increase in the non-performing assets in the third quarter##Yes Bank sees increase in the non-performing assets in the third quarter

Jan 24, 2019 3:38 PM

Ravneet Gill to join Yes Bank as MD & CEO with effect from March 1##Ravneet Gill to join Yes Bank as MD & CEO with effect from March 1

Jan 24, 2019 3:26 PM

Market update: Sensex, Nifty edge up, midcaps underperform, Yes Bank up 6%##Market update: Sensex, Nifty edge up, midcaps underperform, Yes Bank up 6%

The Sensex surged 62 points, or 0.17 percent, to trade at 36,170 at 3.10 pm, while the Nifty edged up by 10 points, or 0.09 percent, to trade at 10,841. Yes Bank shares surged almost 6 percent as the lender announced Ravneet Gill as managing director and chief executive officer. The bank also announced its Q3 results with net profit at Rs 1,001 crore.

Jan 24, 2019 3:11 PM

Colgate-Palmolive Q3 numbers sees growth on all fronts, net profit increases more than 12%##Colgate-Palmolive Q3 numbers sees growth on all fronts, net profit increases more than 12%

Jan 24, 2019 2:49 PM

Here is why HDFC Sec's Dipen Sheth is bullish on ITC, InterGlobe Aviation##Here is why HDFC Sec's Dipen Sheth is bullish on ITC, InterGlobe Aviation

Dipen Sheth, head of institutional research at HDFC Securities, is of the view that Indian markets have not done badly and there's no reason for market players to crib.

"The only thing is the expected huge crack never came, which could be due to steady systematic investment plan (SIP) inflows," Sheth told CNBC-TV18 on Thursday.

Read full report here

Jan 24, 2019 2:49 PM

KPIT Technologies shares pare losses after plunging 44% today##KPIT Technologies shares pare losses after plunging 44% today

Shares of KPIT Technologies plunged nearly 44 percent to hit an intra-day low of Rs 123.10 on Thursday following the demerger of engineering division. The stock opened 37.62 percent lower at Rs 135, below its 200-day moving average.The midcap IT stock has fallen more than 37 percent in the last one month and more than 34 percent in last three months.

Read full report here

Jan 24, 2019 2:35 PM

UltraTech Cement Q3 standalone net profit at Rs 449 crore##UltraTech Cement Q3 standalone net profit at Rs 449 crore

Jan 24, 2019 1:58 PM

Sensex, Nifty largely flat on mixed global cues; Yes Bank loses 1% ahead of Q3 results##Sensex, Nifty largely flat on mixed global cues; Yes Bank loses 1% ahead of Q3 results

Indian shares on Thursday continued a largely flat trend even though the global market began to show a slight recovery.

At 1:22 PM, the BSE Sensex was trading at 36,099 points, 0.03 percent lower, while the NSE Nifty was trading at 10,821 points, 0.08 percent lower. The indices have been largely flat with a negative bias.

In the latest global market update, Asian shares inched up as the Wall Street ended higher after a largely subdued trade. However, political uncertainty in the United States and worries about weakening global economic growth has kept many investors on the sidelines.

Yes Bank is losing nearly 1.42 percent ahead of announcing its Q3 results as investors remain jittery ahead of the bank's new CEO appointment.

Jan 24, 2019 1:35 PM

Global Markets: Asian shares edge up; ECB decision awaited##Global Markets: Asian shares edge up; ECB decision awaited

Asian shares inched up in subdued trade on Thursday after Wall Street ended higher, but political uncertainty in the United States and worries about weakening global economic growth kept many investors on the sidelines.

Financial spreadbetters expect London's FTSE Frankfurt's DAX and Paris's CAC to dip marginally when they open, with investors awaiting news from the European Central Bank's first policy review of the year.

MSCI's broadest index of Asia-Pacific shares outside Japan added 0.3 percent, while Japan's Nikkei average eased 0.1 percent.

"There is no new news to buy, and there are no fresh triggers to sell. Investors are staying on the sidelines," said Yasuo Sakuma, chief investment officer at Libra Investments.

China's benchmark Shanghai Composite and the blue-chip CSI 300 climbed 0.5 percent and 0.6 percent, respectively, taking positive cues from financial firms' profits and the approval for a new technology board in Shanghai. Hong Kong's Hang Seng index rose 0.3 percent.

On Wednesday, Wall Street ended slightly higher after a spate of upbeat earnings reports, including International Business Machines, but lingering concerns about trade tensions and the longest U.S. government shutdown ever limited the advance.

(From Reuters)

Jan 24, 2019 1:19 PM

Dr Reddy's launches anesthetic in US market##Dr Reddy's launches anesthetic in US market

Dr Reddy's Laboratories Thursday announced the launch of Propofol Injectable Emulsion, used for induction of general anesthesia and sedation in intensive care units, in the US market.

Propofol Injectable Emulsion is a therapeutic equivalent generic version of Diprivan (Propofol) Injectable Emulsion," the company said in a BSE filing.

Dr Reddy's said it uses distribution controls to market Propofol Injectable Emulsion, USP, to prevent any misuse.

"Dr Reddy's will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. We require the same commitment from our wholesalers and distributors," the company said.

Quoting IMS Health MAT data for twelve months ending in November 2018, Dr Reddy's Laboratories said Diprivan brand and generic had US sales of approximately USD 310 million.

Shares of Dr Reddy's were trading 0.49 per cent higher at Rs 2,658.45 apiece on the BSE.

(From PTI)

Jan 24, 2019 1:12 PM

Biocon Q3 earnings today: Here's what to expect##Biocon Q3 earnings today: Here's what to expect

Indian biopharmaceutical company Biocon is set to report its third quarter results on Thursday. Here are key factors to watch out for:

It is expected to be a strong quarter for the company.

The revenue is likely to grow around 30 percent.

Margin expansion of around 400 basis points seen, led by higher margin products. One basis point is a hundredth of a percentage point.

Profit is expected to see a growth of 79 percent.

Within the biosimilar business, the one thing which is going to drive growth will be the launch of Pegfilgrastim in the US, the cancer biosimilar.

Branded formulation segment is likely to follow biologics with strong growth of 20-25 percent.

Watch the video for more details here

Jan 24, 2019 12:46 PM

Yes Bank Q3 results today: Gross NPAs, provisions likely to rise##Yes Bank Q3 resultstoday: Gross NPAs, provisions likely to rise

Yes Bank will report its third-quarter earnings on Thursday and the lender is expected to report low single-digit net profit growth.

All eyes will be on the divergence number for FY18, if at all they report. The FY17 divergence was at Rs 6,355 crore and that formed about 4.8 percent of the book.

Loan growth is expected to be above 40 percent last quarter. It was at 41.2 percent. Impact of rising interest rate needs to be seen in terms of the cost of funds. Yes Bank is a big player in the capital market so if at all divergence comes then provisions can be on the higher side. Provisions will be elevated and you can see gross non-performing assets (NPA) rising.

CNBC-TV18’s poll suggests net interest income (NII) growth of 32.3 percent while net profit can grow in single digit less than 3 percent on a year-on-year (YoY) basis.

Watch the video for more details here

Jan 24, 2019 12:31 PM

Edelweiss Financial Services Q3 net rises 18% to Rs 258.35 crore##Edelweiss Financial Services Q3 net rises 18% to Rs 258.35 crore

Edelweiss Financial Services Thursday reported a 18.16 per cent increase in consolidated net profit at Rs 258.35 crore for the third quarter ended December 2018.

The net profit of the company stood at Rs 218.64 crore in the corresponding quarter a year ago.

Its total income increased by 25.46 per cent to Rs 2,790.69 crore in the quarter under review as against Rs 2,224.23 crore in the December quarter of 2017-18, it said in a BSE filing.

Shares of the company were trading 3.30 per cent lower at Rs 155.20 apiece on BSE.

(From PTI)

Jan 24, 2019 12:16 PM

Load more